Study to Evaluate the Efficacy and Safety of TT-00420 (Tinengotinib) in Cholangiocarcinoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Milind Javle, MD
M.D. Anderson Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
32 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Providence Cancer Center
Anchorage, Alaska, United States
- City of Hope
Duarte, California, United States
- University of California, Los Angeles, School of Medicine
Santa Monica, California, United States
- Uso Oncology Network- Rocky Mountain Cancer Centers
Denver, Colorado, United States
- Mount Sinai Medical Center
Miami Beach, Florida, United States
- University of Chicago Medical Center - Duchossis Center for Advanced Medicine
Chicago, Illinois, United States
- University of Maryland - Marlene and Stewart Greenebaum Cancer Center
Baltimore, Maryland, United States
- University of Michigan Comprehensive Cancer Center
Ann Arbor, Michigan, United States
- Henry Ford Health Center
Detroit, Michigan, United States
- Mayo Clinic
Rochester, Minnesota, United States
- Comprehensive Cancer Center of Nevada
Las Vegas, Nevada, United States
- Summit Medical Group - Florham Park Campus
Florham Park, New Jersey, United States
- Roswell Park Comprehensive Cancer Center
Buffalo, New York, United States
- Ruttenberg Treatment Center - Mount Sinai
New York, New York, United States
- Usor Oncology Network- New York Oncology
New York, New York, United States
- Stony Brook University - Long Island Cancer Center
Stony Brook, New York, United States
- University of Cincinnati Cancer Institute
Cincinnati, Ohio, United States
- University Hospitals Seidman Cancer Center
Cleveland, Ohio, United States
- Uso Oncology Network-Northwest Cancer Specialists, P.C.
Portland, Oregon, United States
- Medical College of South Carolina
Charleston, South Carolina, United States
- the University of Tennessee Medical Center
Knoxville, Tennessee, United States
- Sarah Cannon Research Institute at Tennessee Oncology
Nashville, Tennessee, United States
- Methodist Dallas Medical Center
Dallas, Texas, United States
- Parkland Health & Hospital System
Dallas, Texas, United States
- University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center
Dallas, Texas, United States
- Houston Methodist Hospital - Outpatient Center
Houston, Texas, United States
- Ut Md Anderson Cancer Center
Houston, Texas, United States
- Uso Oncology Network-Texas Oncology
Tyler, Texas, United States
- Uso Oncology Network-Virginia Oncology Associates - Brock Cancer Center - Norfolk
Norfolk, Virginia, United States
- Uso Oncology Network-Oncology and Hematology Associates of Southwest Virginia, Inc.
Roanoke, Virginia, United States
- University of Wisconsin School of Medicine and Public Health
Madison, Wisconsin, United States
- Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 7 Dec 2021
- Primary completion
- 28 Feb 2024
- Completion
- 28 Feb 2024
- Last update posted
- 25 Jun 2024
- Registered enrollment
- 55
- Registry id
- NCT04919642
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.